Onto Innovation, OSI Systems, Nano Dimension, NVE, Biodexa Pharmaceuticals, Clene, and Virpax Pharmaceuticals are the seven Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of publicly traded companies that focus on researching, developing and commercializing materials, devices or processes at the nanoscale (one billionth of a meter). Investors buy these equities to gain exposure to firms working on cutting-edge applications—such as advanced electronics, drug delivery systems or novel materials—whose growth potential is tied to breakthroughs in nanotechnology. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.
Onto Innovation (ONTO)
Onto Innovation Inc. engages in the design, development, manufacture, and support of process control tools that performs optical metrology. The company offers lithography systems and process control analytical software. It also offers process and yield management solutions, and device packaging and test facilities through standalone systems for optical metrology, macro-defect inspection, packaging lithography, and transparent and opaque thin film measurements.
Shares of Onto Innovation stock traded up $1.96 during trading hours on Tuesday, reaching $95.75. 566,800 shares of the company were exchanged, compared to its average volume of 974,416. The stock's fifty day moving average is $105.12 and its 200 day moving average is $142.66. The firm has a market cap of $4.68 billion, a PE ratio of 21.66, a PEG ratio of 0.62 and a beta of 1.46. Onto Innovation has a 1 year low of $85.88 and a 1 year high of $238.93.
Read Our Latest Research Report on ONTO
OSI Systems (OSIS)
OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.
NASDAQ OSIS traded down $1.94 during trading hours on Tuesday, hitting $213.75. The company had a trading volume of 89,881 shares, compared to its average volume of 202,445. OSI Systems has a 1-year low of $129.18 and a 1-year high of $241.64. The company has a market cap of $3.59 billion, a PE ratio of 26.00, a price-to-earnings-growth ratio of 1.95 and a beta of 1.28. The business has a 50 day moving average of $218.23 and a 200-day moving average of $197.88. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.38 and a current ratio of 2.11.
Read Our Latest Research Report on OSIS
Nano Dimension (NNDM)
Nano Dimension Ltd., together with its subsidiaries, engages in additive manufacturing solutions in Israel and internationally. The company offers 3D printers, comprising AME systems, which are inkjet printers, that produces Hi-PEDs by depositing proprietary conductive and dielectric substances, as well as integrates in-situ capacitors, antennas, coils, transformers, and electromechanical components; micro additive manufacturing systems, a digital light processing printers (DLP) that achieves production-grade polymer and composite parts; and industrial additive manufacturing systems, that utilizes a patented foil system that fabricates ceramic and metal parts.
NASDAQ NNDM traded down $0.01 during trading hours on Tuesday, hitting $1.42. 1,331,744 shares of the stock were exchanged, compared to its average volume of 1,642,274. The company has a market cap of $307.45 million, a price-to-earnings ratio of -3.54 and a beta of 1.13. Nano Dimension has a 12-month low of $1.34 and a 12-month high of $2.74. The stock has a 50-day moving average of $1.54 and a 200 day moving average of $1.97.
Read Our Latest Research Report on NNDM
NVE (NVEC)
NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.
NASDAQ NVEC traded up $1.00 during mid-day trading on Tuesday, hitting $71.73. The stock had a trading volume of 23,602 shares, compared to its average volume of 27,898. NVE has a 52-week low of $51.50 and a 52-week high of $89.98. The company has a market cap of $346.96 million, a price-to-earnings ratio of 23.06 and a beta of 1.15. The company has a 50 day simple moving average of $66.95 and a 200 day simple moving average of $70.16.
Read Our Latest Research Report on NVEC
Biodexa Pharmaceuticals (BDRX)
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
NASDAQ BDRX traded down $0.01 during mid-day trading on Tuesday, hitting $0.92. The stock had a trading volume of 227,393 shares, compared to its average volume of 1,088,166. Biodexa Pharmaceuticals has a 52-week low of $0.78 and a 52-week high of $41.50. The company has a 50 day simple moving average of $1.25 and a 200 day simple moving average of $2.66. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.75 and a current ratio of 1.75.
Read Our Latest Research Report on BDRX
Clene (CLNN)
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
NASDAQ CLNN traded up $0.07 during mid-day trading on Tuesday, hitting $4.17. The stock had a trading volume of 31,316 shares, compared to its average volume of 89,489. The company has a 50 day simple moving average of $3.26 and a 200 day simple moving average of $3.99. The company has a market cap of $37.46 million, a price-to-earnings ratio of -1.03 and a beta of 0.49. Clene has a 52-week low of $2.28 and a 52-week high of $8.00.
Read Our Latest Research Report on CLNN
Virpax Pharmaceuticals (VRPX)
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
NASDAQ:VRPX traded up $0.02 during trading hours on Tuesday, reaching $0.30. 41,956 shares of the company traded hands, compared to its average volume of 201,312. Virpax Pharmaceuticals has a 1-year low of $0.13 and a 1-year high of $84.75. The firm's 50-day moving average is $0.25 and its 200-day moving average is $3.96.
Read Our Latest Research Report on VRPX
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Onto Innovation, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Onto Innovation wasn't on the list.
While Onto Innovation currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
